Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS) and generally spreads to the nearby brain tissues. Its symptoms include seizures, constant headaches, vomiting, blurred or double vision, and difficulty in speaking.
A key factor contributing to growth of the glioblastoma multiforme market is the rising number of brain and other nervous system cancers occurring worldwide. Globally, GBM accounted for 54% of new gliomas and 45% of primary malignant tumors. According to the U.S National Cancer Institute 2015 estimates 22,850 adults comprising 10,280 women and 12,630 men were diagnosed with brain and other forms of nervous system cancer. The rising number of cases of GBM is expected to drive the glioblastoma multiforme market during the forecast period. Increase in funding for companies involved in the research on GBM is also contributing to the growth of the glioblastoma multiforme market. For instance, in February 2018, Novocure announced that it would receive fresh infusion of capital from BioPharma Credit PLC, which is an investment fund of Pharmakon Advisors, LP. The term loan agreement for US$ 150 Mn will be used by Novocure to accelerate its R&D on improved treatment option for GBM. Additionally, companies are focusing on the development of new drugs and therapies in order to maintain their competitive advantage and penetrate new regional markets. In December 2017, Genentech, a subsidiary of Roche, announced that it had received approval from U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) to be used in the treatment glioblastoma in adults. In September 2017, the FDA approved Amgen’s MVASI (bevacizumab-awwb), which is the first bevacizumab biosimilar as well as the first anti-cancer biosimilar to be approved for the treatment of five types of cancer, including GBM. In July 2016, Mylan launched Temozolomide capsules, the generic version of Merck’s Temodar, in the U.S. The capsules are indicated for use concomitantly with radiotherapy in adult patients for the treatment of glioblastoma multiforme.
The glioblastoma multiforme market can be segmented based on treatment type, end-user, and geography. In terms of treatment type, the market can be divided into drugs, electric-field therapy, and others. The drugs segment can be further divided into antineoplastic agents, anticonvulsants, and corticosteroids. Based on end-user, the glioblastoma multiforme market can be classified into hospitals, ambulatory surgical centers, and specialty clinics.
Geographically, the global glioblastoma multiforme market can be segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global glioblastoma multiforme market due to rise in funding for research & development of novel drugs and therapies for the treatment of glioblastoma. North America is followed by Europe and Asia Pacific. Grant of regulatory approval for new treatment therapies for glioblastoma is propelling the growth of the glioblastoma multiforme market in Asia Pacific. In December 2017, the Ministry of Health, Labour and Welfare in Japan approved the recommendation of the Central Social Insurance Medical Council (Chuikyo) for providing reimbursement for Novocure’s Optune, which is a non-invasive, portable device used in the treatment of newly diagnosed glioblastoma.
Prominent players operating in the global glioblastoma multiforme market are Bexion Pharmaceuticals, LLC, Bristol-Myers Squibb, Double Bond Pharmaceutical, Diffusion Pharmaceuticals, F. Hoffmann-La Roche AG., GW Pharmaceuticals, plc. Merck & Co., Inc., MimiVax, LLC, Novocure, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.
TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.
Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:
Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.
Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.
Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.